drug
Alzheimer's Disease
Preclinicalupdated 6mo agoby Metallomix Inc
Preclinicalcommunity read0 votes
🐶 often sniffed alongside
top 8- tagAlzheimer's Disease51 co-mentions · 50 sources
- companyNorthwestern University3 co-mentions · 3 sources
- companyEmory University2 co-mentions · 2 sources
- companyUniversity of Florida2 co-mentions · 2 sources
- companyMassachusetts General Hospital2 co-mentions · 2 sources
- companyWake Forest University1 co-mentions · 1 sources
- drugbupropion hydrochloride ER1 co-mentions · 1 sources
- drugBUPROPION HYDROCHLORIDE1 co-mentions · 1 sources
indications
indications
Alzheimer's Disease
all catalysts(0)
nothing on the calendar yet
Trials studying Alzheimer's Disease
News(10)
- Biogen’s tau therapy drives bigger benefits in 2-year Alzheimer’s updateBiogen has linked its tau-targeting antisense oligonucleotide to a further slowing of clinical decline after two years, leading analysts to hail the strengthening of evidence supporting late-phase…fiercebiotech · 6h ago
- Priavoid’s Alzheimer’s pill fails to prove efficacy in phase 2 trialPriavoid’s pill for Alzheimer's disease has failed to prove its effectiveness in a phase 2 dementia study, although the German biotech pointed to encouraging signs in the longer-term data.fiercebiotech · 11h ago
- Cognito phase 3 flops in light-and-sound Alzheimer's trial, but sees ‘signal’ for HOPECognito Therapeutics said its phase 3 HOPE study of Spectris AD, an investigational, non-invasive, at-home Alzheimer's therapy that uses light and sound stimulation to engage brain activity, failed…fiercebiotech · 12h ago
- #CTAD26: Cognito plans FDA submission of light and sound therapy for Alzheimer’sBOSTON — A decade ago, neuroscientists at MIT published data that seemed too good, or perhaps just too wacky, to be true. Light flickered at just the right frequency induced brain waves that appear…endpoints · 1d ago
- CTAD 2026: AriBio’s Alzheimer’s candidate slows cognitive decline as monotherapyAt the 2026 Clinical Trials on Alzheimer’s Disease conference, AriBio reported that AR1001 slowed cognitive decline more than placebo in patients not taking other drugs for the disease.biospace · 1d ago
- AriBio’s oral Alzheimer’s drug meets monotherapy goal in phase 3 as Fosun weighs licensing optionAriBio’s erectile dysfunction med-turned Alzheimer’s disease candidate mirodenafil has delivered some mixed results from a global phase 3 trial. Fosun Pharma has an option to in-license the PDE5 in…fiercebiotech · 1d ago
- J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depressionDelix Therapeutics has raised $100 million in a series C round backed by the likes of Johnson & Johnson to advance a phase 2-ready non-hallucinatory psychedelic therapy for depression.fiercebiotech · 9d ago
- This week in charts: 3 drug launches Wall Street is watchingThe latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of medicines highlighted in quarterly earnings this week.biopharma_dive · 12d ago
- Eli Lilly scraps phase 2 Alzheimer's program after drug falls short of expectationsEli Lilly has dropped its phase 2 Alzheimer's disease program for mevidalen, marking another setback for the experimental drug as the Big Pharma expands its neuroscience pipeline through multibilli…fiercebiotech · 20d ago
- BMS walks away from $80M neurodegeneration bet after phase 1Bristol Myers Squibb has scrapped a phase 1 program it bet $80 million on just two years ago.fiercebiotech · 20d ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that